We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Biomarkers Predict Likelihood of Castleman Disease Treatment Response

By LabMedica International staff writers
Posted on 13 Sep 2021
Print article
Image: High magnification micrograph of Castleman disease, hyaline vascular variant, also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia (Photo courtesy of Wikimedia Commons)
Image: High magnification micrograph of Castleman disease, hyaline vascular variant, also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia (Photo courtesy of Wikimedia Commons)
Biomarkers have been found in the blood that can be used to predict which patients with idiopathic multicentric Castleman disease are more likely to respond to siltuximab, the only [U.S.] Food and Drug Administration (FDA) approved treatment for the disorder.

Idiopathic multicentric Castleman disease (iMCD) is a subtype of the rare blood disorder, Castleman disease. This is a group of lymphoproliferative disorders characterized by lymph node enlargement, characteristic features on microscopic analysis of enlarged lymph node tissue, and a range of symptoms and clinical findings. People with iMCD have enlarged lymph nodes in multiple regions and often have flu-like symptoms, abnormal findings on blood tests, and dysfunction of vital organs, such as the liver, kidneys, and bone marrow. iMCD has features often found in autoimmune diseases and cancers, but the underlying disease mechanism is unknown. About 35% of iMCD patients die within five years of diagnosis.

Interleukin-6 (IL-6) is an established driver of iMCD in approximately one-third of patients. Siltuximab, a monoclonal antibody targeting IL-6, is the only medication approved by the FDA for the treatment of iMCD. Few options exist for siltuximab non-responders, and no validated tests are available to predict likelihood of response.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) sought to develop a test to predict likelihood that an iMCD patient would respond positively to siltuximab treatment.

For this work, the investigators analyzed blood samples from 88 iMCD patients and measured 1,178 blood proteins in each of those samples. The results were subsequently validated in an independent cohort of 23 iMCD patients. In addition, samples from 60 patients with clinico-pathologically overlapping diseases (human herpesvirus-8(HHV8)-associated Castleman disease, Hodgkin lymphoma, rheumatoid arthritis) and 44 healthy controls were analyzed for comparison.

Results revealed a cluster of seven blood proteins that was able to effectively predict the subgroup of patients who were most likely to respond to siltuximab.

“This discovery has the potential to improve precision medicine for iMCD - the concept that the right patient is given the right drug at the right time. Knowing which patients are likely to benefit from which drugs is a key piece of this puzzle," said senior author Dr. David Fajgenbaum, assistant professor of translational medicine and human genetics at the University of Pennsylvania School of Medicine.

The iMCD study was published in the August 26, 2021, online edition of the journal Blood Advances.

Related Links:
University of Pennsylvania School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.